Happy Authors

Recently Published Articles
  • 2020, May

    original research

    Correlation of 18F-Fluorodeoxyglucose Glucose Uptake by Liver Cancer and Transcriptional Regulation of the Warburg Effects in ATT-MYC Mouse Model of Liver CancerOpen Access

    PDF463.83 KB 463.83 KB
    Full-Text (HTML)
    Abstract [+]

    Background

    It was previously reported that diethylnitrosamine (DEN) enhanced liver cancer progression in ATT-MYC mouse model of liver cancer. Radiogenomics is a new tool in advanced science technology that gives information on tumor biology, non-tumor surrounding tissue, the degree of tumor size and presence of necrosis of cells especially with joined micro computed tomography – positron emission tomographys (CT/PETs).

    Aim

    To evaluate the correlation of gene expression and non-invasive microPET information of the liver tumors at different points of the stage of growth.

    Methods

    Exon array expression of the liver of ATT-MYC mice treated with DEN or butylated hydroxytoluene (BHT) compared to control non-transgenic mice were analyzed by array track and the current data were also compared to microarray expression of liver tumor of ATT-MYC mice.

    Results

    The expression of genes responsible for glucose transport such as glut1, 3, 4, hk1, slc1a5, slc1a1, slc1a4, slc1a2, gp6c and gpc-1-3-4 were up-regulated significantly in DEN-treated transgenic mice immediately after end of treatment (p≤0.05), while glut2 (fold change 0.9503, p-value 0.4385) and hk2 (fold change 3.0589, p-value 0.0565) genes were increased not significantly immediately after end of treatment. Additionally, at 4.5-months of observation after the end of treatment slc1a5, slc38a2, glut1, glut4 and gpc3-4 genes had a significant fold change in liver tumor tissue in DEN treated mice when compared to BHT or control transgenic or non-transgenic one. While hk1, 2, slc5a1, slc1a4, glut2, glut3, g6pc and gpc-1 genes were increased non-significantly in the liver of treated mice when compared to control group at 4.5-months of observation after the end of treatment. Notably, c-myc, hif-1 and aldoa glycolytic genes were expressed significantly both time points of 4 and 8.5-months while ldhb, hk-2 and PKM2 were increased non-significantly in DEN treatment when compared to BHT/control non-transgenic animals.

    Conclusion

    There is a definitive correlation between genes responsible for glucose transport and 18F-Fluorodeoxyglucose (FDG) uptake in the early and advanced degree of liver carcinogenesis. This study of glucose pathway in Hepatocellular carcinoma (HCC) at different stages of early and advanced one is the potential for therapeutic anticancer therapy.

    Keywords

    18-FFluorodeoxyglucose (FDG); MicroPET; Exon array expression; Hepatocellular carcinoma (HCC); Att-myc transgenic mice; Diethylnitrosamine (DEN), Butylated hydroxytoluene (BHT); Glucose metabolism.


About the Journal

Liver Research – Open Journal (LROJ) aims to publish the latest research in the aspects of the Liver and its diseases, treatments, and updates to enhance the existing actions.

The liver is known to perform varied crucial functions like protein synthesis, detoxification, metabolism, and biochemical production. The liver is the only organ that supports every organ in the body. The liver is prone to several diseases due to its deliberated position and multidimensional purpose.

Some of the common liver diseases include liver cancer, hepatitis infection, alcohol damage, genetic and metabolic diseases and some among them are treated and some needs transplantation.

However, Openventio aims to widespread all the detailed matters related to the functioning of Liver, treatments and its advancement.

Aims and Scope

Liver Research – Open Journal (LROJ) is open dissemination and robust discussion in the areas of Liver and clinical research on all aspects of the Liver and its diseases.

LROJ covers a wide array of subjects as given below Scope of this journal includes:

  • Chronic liver diseases
  • Liver transplantation
  • Pathogenesis of liver diseases
  • Autoimmune liver diseases
  • Non-alcoholic fatty liver disease (NAFLD)
  • Molecular research in hepatology
  • Pancreaticobiliary Diseases and treatment
  • Nutrition and liver cancer
  • Liver cancer
  • Liver injury or damage

Submissions for this Journal are accepted from the very basic Liver Research to the latest treatments and advancements. This journal publishes articles on basic to advanced liver research.

All researchers, physicians, pharmacologists, clinicians, surgeons, general practitioners, educators, students and nurses working on liver research are encouraged to contribute to this journal.

The journal accepts all types of articles such as original research, review, case report, mini review, editorial, short communications, book review, opinion, commentary, letter to the Editor, conference proceedings, technical report, errata, illustrations, etc.

We are open to receive comments or any corrections from any potential scientists to improve the quality of our journal. We would be interested to hear any comments on the improvement of journal quality from you.